Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide and chemoembolisation with or without dendritic cell vaccine in hepatocellular carcinoma
2011-001690-62Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Sep 2014
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous dendritic cells HepG2-pulsed vaccine in hepatocellular carcinoma (HCC) (2 arms), sponsored by University of Birmingham. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
autologous dendritic cells HepG2-pulsed vaccine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-001690-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001690-62.